Inge Marie Svane

Københavns Universitet

Denmark

Research Interests

Explore related searches

Professors in Immunology

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (30)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Collaborators (18)

Carolina Barra

Technical University of Denmark

DENMARK

View details

Maartje Schermer

Erasmus University Rotterdam

NETHERLANDS

View details

Melanie Lindenberg

University of Twente

NETHERLANDS

View details

Nikolaj Pagh Kristensen

University Hospital Erlangen

GERMANY

View details

Eva Ellebaek

Copenhagen University Hospital

DENMARK

View details

Jorge Sierra-Pérez

Associate Professor

Universidad de Zaragoza

SPAIN

View details

Akseli Hemminki

University of Helsinki

FINLAND

View details

Özcan Met

Københavns Universitet

DENMARK

View details

Elena Semino

University of Lancaster

UNITED KINGDOM

View details

Valesca Retèl

Erasmus University Rotterdam

NETHERLANDS

View details

Christina H Ruhlmann

Associate Professor

University of Southern Denmark

DENMARK

View details

Paul Rayson

University of Lancaster

UNITED KINGDOM

View details

Mads Hald Andersen

Professor, dr.techn., Director

DENMARK

View details

Fernando Secomandi

Delft University of Technology

NETHERLANDS

View details

Henrik Schmidt

Consultant, Ass. Prof

Aarhus University Hospital

DENMARK

View details

Marco Donia

Copenhagen University Hospital

DENMARK

View details

Renske ten Ham

Assistant Professor

UMC Utrecht

NETHERLANDS

View details

Mona Aarenstrup Karlsen

Copenhagen University Hospital

DENMARK

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Inge Marie Svane

Research Interests

Explore related searches

Contact this professor

Articles (30)

Immune checkpoint inhibition in metastatic or non-resectable melanoma after failure of adjuvant anti-PD-1 treatment. A EUMelaReg real-world evidence study

Health-related quality of life of patients with metastatic melanoma treated with tumor-infiltrating lymphocytes compared with ipilimumab in a randomized phase III trial

Identification of protein biomarker candidates associated with organ-specific immune-related toxicity and response to management by plasma proteomics.

Long-term clinical outcome of patients with metastatic melanoma and initial stable disease during anti-PD-1 checkpoint inhibitor immunotherapy with pembrolizumab.

Surgical considerations for tumour-infiltrating lymphocyte therapy in melanoma: results from a randomized phase III trial.

Impact of assessment-to-treatment interval and metastatic biopsy site on the predictive value of PD-L1 expression at the 1 % cut-off level in melanoma.

Safety of adoptive therapy with tumor-infiltrating lymphocytes and high-dose recombinant interleukin-2 in advanced cutaneous melanoma: a systematic review and meta-analysis.

Steroid-refractory severe immune-related mucositis following adjuvant anti-PD-1 therapy for resectable melanoma: a case report.

Unlocking tumor-infiltrating lymphocyte potential with CRISPR-Cas9.

Safety and efficacy of combined treatment with tumor-infiltrating lymphocytes and oncolytic adenovirus TILT-123 in metastatic melanoma.

Real-World Cardiotoxicity in Metastatic Melanoma Patients Treated with Encorafenib and Binimetinib

Efficacy of Ipilimumab and Nivolumab in Patients with Melanoma and Brain Metastases—A Danish Real-World Cohort

Prospective Assessment of Fluorine-18-Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography (FDG-PET/CT) for Early Identification of Checkpoint-Inhibitor-Induced Pseudoprogression

Cost-effectiveness of treating advanced melanoma with tumor-infiltrating lymphocytes based on an international randomized phase 3 clinical trial

Harnessing neoantigen-specific T cells for precision cancer immunotherapy.

Biomarkers for response to TIL therapy: a comprehensive review.

Outcome of adjuvant immunotherapy in a real-world nation-wide cohort of patients with melanoma.

Improving shared decision-making about cancer treatment through design-based data-driven decision-support tools and redesigning care paths: an overview of the 4D PICTURE project.

New expert advice on cancer in pregnancy.

Reduced mitochondrial respiration in peripheral T cells after paediatric heamatopoietic stem cell transplantation.

Pre-existing TGF-β-specific T-cell immunity in patients with pancreatic cancer predicts survival after checkpoint inhibitors combined with radiotherapy

of intact tumor fragments with anti-PD-1 and anti-CTLA-4 influences the expansion and specificity of tumor-infiltrating lymphocytes

Long-term follow-up of anti-PD-1 naïve patients with metastatic melanoma treated with IDO/PD-L1 targeting peptide vaccine and nivolumab

Uncoupling CD4+ TIL-mediated tumor killing from JAK-signaling in melanoma.

ASO Visual Abstract: Earlier Recurrence Detection Using Routine FDG PET-CT Scans in Surveillance of Stage IIB to IIID Melanoma-A National Cohort Study of 1480 Patients.

Letter: be careful of gastrointestinal CMV infection in adverse event from ICIs therapy in solid tumours-Authors' reply.

TIL Therapy: Facts and Hopes.

Neoepitope load, T cell signatures and PD-L2 as combined biomarker strategy for response to checkpoint inhibition immunotherapy.

An arginase1- and PD-L1-derived peptide-based vaccine for myeloproliferative neoplasms: A first-in-man clinical trial.

Combination therapy with immune check point inhibitors and acute kidney injury.

Collaborators (18)

Carolina Barra

Maartje Schermer

Melanie Lindenberg

Nikolaj Pagh Kristensen

Eva Ellebaek

Jorge Sierra-Pérez

Akseli Hemminki

Özcan Met

Elena Semino

Valesca Retèl

Christina H Ruhlmann

Paul Rayson

Mads Hald Andersen

Fernando Secomandi

Henrik Schmidt

Marco Donia

Renske ten Ham

Mona Aarenstrup Karlsen

Make your next move.

Impact of assessment-to-treatment interval and metastatic biopsy site on the predictive value of PD-L1 expression at the 1 % cut-off level in melanoma.